Primary percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: does the choice of fibrinolytic agent impact on the importance of time-to-treatment?

The American Journal of Cardiology
Brahmajee K NallamothuEric R Bates

Abstract

The mortality benefit associated with primary percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction may be lost if door-to-balloon time is delayed by >1 hour compared with tissue plasminogen activator therapy door-to-needle time. When a substantial delay in initiating primary PCI is likely, reperfusion therapy with second- or third-generation fibrinolytic agents should be strongly considered.

References

Aug 1, 1993·Bratislavské lekárske listy·J MurínR Uhliar
Oct 13, 1998·Journal of the American College of Cardiology·P N CasaleL M Eby
Oct 1, 2003·The American Journal of Cardiology·Brahmajee K Nallamothu, Eric R Bates
Dec 10, 2003·Circulation·Giovanni Melandri

❮ Previous
Next ❯

Citations

Jul 8, 2010·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Ralf BirkemeyerWerner Jung
Mar 17, 2010·Wiener medizinische Wochenschrift·Alois SuessenbacherHannes F Alber
Oct 19, 2007·The New England Journal of Medicine·Brahmajee K NallamothuHarlan M Krumholz
Mar 26, 2009·European Journal of Emergency Medicine : Official Journal of the European Society for Emergency Medicine·Patrick GoldsteinJean Michel Juliard
Aug 24, 2011·Circulation·Harlan M KrumholzJeptha P Curtis
Apr 10, 2013·Health Economics Review·Ralf BirkemeyerSteffen Wahler
Jun 20, 2007·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Jacobus S de VilliersUNKNOWN Calgary STEMI QIHI group
Jan 6, 2009·Wiener klinische Wochenschrift·Michael JoannidisChristian J Wiedermann
Dec 7, 2010·Progress in Cardiovascular Diseases·Nathaniel W NilesUNKNOWN Dartmouth-Hitchcock ST Elevation Myocardial Infarction Process Upgrade Project (STEPUP) Group
Oct 12, 2010·Cardiovascular Revascularization Medicine : Including Molecular Interventions·Abdul HakeemMehmet Cilingiroglu
Jan 10, 2009·International Journal of Cardiology·Samip Vasaiwala, Mladen Vidovich
Jun 30, 2007·Journal of Internal Medicine·E V Gelfand, C P Cannon
Oct 4, 2005·Emergency Medicine Clinics of North America·Chris A Ghaemmaghami, David R Burt
Aug 25, 2015·The American Journal of Emergency Medicine·Mehmet Ali AstarciogluBasri Amasyali
Mar 7, 2009·Journal of the American College of Cardiology·Samip Vasaiwala, Mladen I Vidovich
Oct 4, 2005·Journal of the American College of Cardiology·Harlan M Krumholz
Apr 6, 2005·Journal of the American College of Cardiology·William W O'NeillCindy L Grines
Oct 18, 2008·Journal of the American College of Cardiology·Elliott M Antman
Mar 17, 2005·European Heart Journal·Sigmund SilberUNKNOWN Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology
Jul 20, 2012·Circulation. Cardiovascular Quality and Outcomes·John E Brush
Jun 6, 2020·Journal of the American Heart Association·Amgad Mentias, Saket Girotra
Aug 2, 2005·European Heart Journal·Kurt HuberUNKNOWN Task Force on Pre-hospital Reperfusion Therapy of the Working Group on Thrombosis of the ESC
Aug 3, 2021·Cardiovascular Revascularization Medicine : Including Molecular Interventions·Corinne S BabiolakisWael Abuzeid

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.